Modulation of 11β-hydroxysterold dehydrogenase expression by bombesin: A possible mechanism for glucocorticoid resistance in androgen independent prostate cancer

Hormone and Metabolic Research

Volumn 40, Issue 11, 2008, Pages 772-778

  Lee, J G ^a   Ge, R ^a   Hardy, D O ^a   Leong, K ^a   Nanus, D M ^a   Hardy, M P ^a   Shen, R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

11 hydroxysteroid dehydrogenases; Bombesin; Glucocorticoid; Neuroendocrine differentiation; Prostate cancer

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; BOMBESIN; BOMBESIN ANTAGONIST; BOMBESIN RECEPTOR; CORTICOSTERONE; DEHYDROCORTICOSTERONE; GLUCOCORTICOID; H 3038; HYDROCORTISONE; INTERLEUKIN 8; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVITY; HORMONE ACTION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION; TUMOR CELL LINE; VASCULARIZATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; BOMBESIN; CELL LINE, TUMOR; DRUG RESISTANCE; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-8; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RECEPTORS, BOMBESIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 57149116951     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1080897     Document Type: Article

References (33)

1. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocrin Relat Cancer 1999; 6: 487-502
2. Saika T, Kusaka N, Tsushima T, Yamato T, Ohashi T, Suyama B, Arata R, Nasu Y, Kumon H. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients. Intl J Urol 2001; 8: 290-294
3. Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol 2007; 52 (Suppl): S26-S34
4. Wu WS, Wang FS, Yang KD, Huang C, Kuo Y. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol 2006; 126: 1264-1271
5. Oliver A, Ciulla TA. Corticosteroids as antiangiogenic agents. Ophthalmol Clin North Am 2006; 19: 345-351
6. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 2006; 12: 3003-3009
7. Draper N, Stewart PM. 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endo 2005; 186: 251-271
8. Ge RS, Dong Q, Niu EM, Sottas CM, Hardy DO, Catterall JF, Latif SA, Morris DJ, Hardy MP. 11β-Hydroxysteroid dehydrogenase 2 in rat leydig cells: its role in blunting glucocorticoid action at physiological levels of substrate. Endocrinology 2005; 146: 2657-2664
9. Kofler R, Schmit S, Kofler A, Ausserlechner MJ. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol 2003; 178: 19-27
10. Wu JT, Erickson AJ, Tsao KC, Wu TL, Sun CF. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci 2000; 30: 175-178
11. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59: 1152-1159
12. Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Onc 2007; 18: 1457-1466
13. Monder C, Lakshmi V. Corticosteroid 11 beta-dehydrogenase of rat tissues: immunological studies. Endocrinology 1990; 126: 2435-2443
14. Ge RS, Hardy MP. Protein kinase C increases 11beta-hydroxysteroid dehydrogenase oxidation and inhibits reduction in rat Leydig cells. J Andrology 2002; 23: 135-143
15. Gong J, Zhu J, Goodman OB, Pestell RG, Schlegel PN, Nanus DM, Shen R. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 2006; 23: 2011-2021
16. Quinkler M, Zehnder D, Lepenies J, Petrelli MD, Moore JS, Hughes SV, Cockwell P, Hewison M, Stewart PM. Expression of renal 11β hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. Eur J Endo 2005; 153: 291-299
17. Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 1999; 84: 4172-4177
18. Sun K, Yang K, Challis JR. Regulation of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone, estrogen, and the cyclic adenosine 5′-monophosphate pathway in cultured human placental and chorionic trophoblasts. Biol Reprod 1998; 58: 1379-1384
19. Sumitomo M, Milowsky M, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001; 61: 3294-3298
20. Nath N, Lakshmi V, Rosenthal JC. Presence of 11 beta-hydroxysteroid dehydrogenase enzyme in the human prostate tumor cell line LNCaP. Prostate 1993; 23: 225-233
21. Zhu J, Gong JY, Goodman OB, Cartegni L, Nanus DM, Shen R. Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. BBA-Mol, Cell Res 2007; 1773: 1087-1094
22. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135-148
23. Sumitomo M, Shen R, Goldberg JS, Dai J, Navarro D, Nanus DM. Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase δ degradation. Cancer Res 2000; 60: 6590-6596
24. Zheng R, Iwase A, Shen R, Goodman OB, Sugimoto N, Takuwa Y, Lerner DJ, Nanus DM. Neuropeptide stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene 2006; 25: 5942-5952
25. Dai J, Shen R, Nanus DM. Synergistic activation of androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 2002; 8: 2399-2405
26. Paulsen SK, Pedersen SB, Jørgensen JO, Fisker S, Christiansen JS, Flyvbjerg A, Richelsen B. Growth Hormone (GH) substitution in GH-deficient patients inhibits 11ß-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 2006; 91: 1093-1098
27. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Rev 2004; 25: 831-866
28. Levine L, Lucci 3rd JA, Pazdrak B, Cheng JZ, Guo YS, Townsend Jr CM, Hellmich MR. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003; 63: 3495-3502
29. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CPN. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000; 6: 2104-2109
30. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974
31. Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 2005; 105: 782-787
32. Herr I, Gassler N, Friess H, Buchler MW. Regulation of differential proand anti-apoptotic signaling by glucocorticoids. Apoptosis 2007; 12: 271-291
33. Flaig TW, Bargawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006; 107: 266-274